Investigation of the Possible Correlation between Idiopathic Parkinson's Disease and Diabetes Mellitus in Egyptian Patients: A Pilot Study.

IF 1.7 Q4 NEUROSCIENCES

Neurology Research International Pub Date : 2021-11-12 eCollection Date: 2021-01-01 DOI:10.1155/2021/2838669

Afnan AwadAllah Elgnainy, Mohammad Ismail Hamed, Wael Osman Mohamed, Nagwa Ali Sabri

{"title":"Investigation of the Possible Correlation between Idiopathic Parkinson's Disease and Diabetes Mellitus in Egyptian Patients: A Pilot Study.","authors":"Afnan AwadAllah Elgnainy, Mohammad Ismail Hamed, Wael Osman Mohamed, Nagwa Ali Sabri","doi":"10.1155/2021/2838669","DOIUrl":null,"url":null,"abstract":"Objectives: To study the diabetes-Parkinson's disease (PD) linkage.Methods: The investigators recorded the rapid eye movement sleep behavior disorder screening questionnaire (RBDSQ) score for 60 diabetic patients: 30 patients were treated with metformin-inclusive sulfonylurea and 30 patients were treated with sulphonylurea(s) monotherapy and matched with 30 controls. We evaluated blood glucose kinetics during a 75 g oral glucose tolerance test for (22) nondiabetic parkinsonian patients and (10) controls. The motor complications scores were recorded for all parkinsonian patients using the relevant parts of the Unified Parkinson's Disease Rating Scale (UPDRS) part IV.Results: Diabetics recorded higher scores of RBDSQ than controls (p < 0.001), with no differences related to antidiabetic therapy. In nondiabetic PD patients, after oral glucose, blood glucose was significantly higher at T1 (p < 0.001) than controls. Moreover, the total area under the time curve for blood glucose levels was significantly higher in PD compared to controls (281.22 ± 52.25 vs. 245.65 ± 48.63 mg.hr./dL; p=0.013). Higher blood glucose levels were associated with motor abnormalities. Diabetic PD patients recorded higher scores of UPDRS (p < 0.001).Conclusion: Diabetes mellitus and Parkinson's disease are linked, which raises concerns about either of them, probably increasing the risk of the other. This trial is registered with NCT03685357.","PeriodicalId":19124,"journal":{"name":"Neurology Research International","volume":null,"pages":null},"PeriodicalIF":1.7000,"publicationDate":"2021-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8604607/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurology Research International","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2021/2838669","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"NEUROSCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: To study the diabetes-Parkinson's disease (PD) linkage.

Methods: The investigators recorded the rapid eye movement sleep behavior disorder screening questionnaire (RBDSQ) score for 60 diabetic patients: 30 patients were treated with metformin-inclusive sulfonylurea and 30 patients were treated with sulphonylurea(s) monotherapy and matched with 30 controls. We evaluated blood glucose kinetics during a 75 g oral glucose tolerance test for (22) nondiabetic parkinsonian patients and (10) controls. The motor complications scores were recorded for all parkinsonian patients using the relevant parts of the Unified Parkinson's Disease Rating Scale (UPDRS) part IV.

Results: Diabetics recorded higher scores of RBDSQ than controls (p < 0.001), with no differences related to antidiabetic therapy. In nondiabetic PD patients, after oral glucose, blood glucose was significantly higher at T1 (p < 0.001) than controls. Moreover, the total area under the time curve for blood glucose levels was significantly higher in PD compared to controls (281.22 ± 52.25 vs. 245.65 ± 48.63 mg.hr./dL; p=0.013). Higher blood glucose levels were associated with motor abnormalities. Diabetic PD patients recorded higher scores of UPDRS (p < 0.001).

Conclusion: Diabetes mellitus and Parkinson's disease are linked, which raises concerns about either of them, probably increasing the risk of the other. This trial is registered with NCT03685357.

Abstract Image

查看原文本刊更多论文

埃及患者中特发性帕金森病与糖尿病之间可能存在的相关性调查：一项试点研究。

目的：研究糖尿病与帕金森病（PD）之间的联系：研究糖尿病与帕金森病（PD）的联系：研究人员记录了 60 名糖尿病患者的快速眼动睡眠行为障碍筛查问卷（RBDSQ）得分：30名患者接受二甲双胍-磺脲类药物治疗，30名患者接受磺脲类药物单药治疗，并与30名对照组患者进行配对。我们评估了 22 名非糖尿病帕金森患者和 10 名对照组患者在 75 克口服葡萄糖耐量试验期间的血糖动力学。我们使用统一帕金森病评分量表（UPDRS）第四部分的相关内容记录了所有帕金森病患者的运动并发症评分：糖尿病患者的 RBDSQ 评分高于对照组（P < 0.001），差异与抗糖尿病治疗无关。非糖尿病帕金森病患者在口服葡萄糖后，血糖在T1显著高于对照组（P < 0.001）。此外，与对照组相比，PD 患者血糖水平时间曲线下的总面积明显更高（281.22 ± 52.25 vs. 245.65 ± 48.63 mg.hr./dL；p=0.013）。较高的血糖水平与运动异常有关。糖尿病帕金森病患者的UPDRS评分更高（p < 0.001）：结论：糖尿病和帕金森病是相关联的，这引起了人们对其中任何一种疾病的担忧，因为它们可能会增加另一种疾病的风险。该试验已在 NCT03685357 上注册。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Neurology Research International NEUROSCIENCES-

CiteScore

3.50

自引率

0.00%

发文量

审稿时长

17 weeks

期刊介绍： Neurology Research International is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies focusing on diseases of the nervous system, as well as normal neurological functioning. The journal will consider basic, translational, and clinical research, including animal models and clinical trials.